We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is tran... Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Show more
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that...
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 BOSTON, July 11, 2024 (GLOBE NEWSWIRE...
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its...
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024...
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the...
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q...
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash...
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.41 | -14.5093317279 | 16.61 | 17.25 | 13.93 | 33077 | 15.46910821 | CS |
| 4 | -2.8 | -16.4705882353 | 17 | 20.45 | 13.93 | 52933 | 16.60363344 | CS |
| 12 | -10.29 | -42.0171498571 | 24.49 | 25.69 | 13.93 | 49251 | 19.07176239 | CS |
| 26 | 5.2 | 57.7777777778 | 9 | 26.3789 | 8.01 | 38626 | 18.62449259 | CS |
| 52 | 0.7 | 5.18518518519 | 13.5 | 26.3789 | 4.22 | 37793 | 13.2854098 | CS |
| 156 | 0.7 | 5.18518518519 | 13.5 | 26.3789 | 4.22 | 37793 | 13.2854098 | CS |
| 260 | 0.7 | 5.18518518519 | 13.5 | 26.3789 | 4.22 | 37793 | 13.2854098 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
